Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Change in Account Payables (2016 - 2025)

Dare Bioscience (DARE) has disclosed Change in Account Payables for 11 consecutive years, with $518208.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables rose 160.18% year-over-year to $518208.0, compared with a TTM value of $773280.0 through Sep 2025, up 119.63%, and an annual FY2024 reading of -$1.9 million, down 242.14% over the prior year.
  • Change in Account Payables was $518208.0 for Q3 2025 at Dare Bioscience, up from -$152082.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.5 million in Q2 2023 and bottomed at -$1.7 million in Q2 2022.
  • Average Change in Account Payables over 5 years is $47095.7, with a median of $7674.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables plummeted 787.67% in 2021, then soared 506.37% in 2022.
  • Year by year, Change in Account Payables stood at $1.5 million in 2021, then crashed by 196.79% to -$1.4 million in 2022, then fell by 10.53% to -$1.6 million in 2023, then skyrocketed by 125.42% to $407154.0 in 2024, then grew by 27.28% to $518208.0 in 2025.
  • Business Quant data shows Change in Account Payables for DARE at $518208.0 in Q3 2025, -$152082.0 in Q2 2025, and $407154.0 in Q4 2024.